The Language of Editing: Why Britain’s CRISPR Sector Needs a Common Lexicon

A consent form is not a slogan

In November 2026, the UK’s gene-editing conversation is more sophisticated than it was a decade ago. Trials are no longer hypothetical; hospital trusts, regulators and patient groups are discussing schedules, follow-up and funding. Yet the vocabulary has not kept pace. In clinics, headlines and consent forms, words such as cure, treatment, edit and functional cure are still used as if they were interchangeable. They are not.

This is not a complaint about jargon. Specialists need precise technical language. The problem is that public and patient-facing communication often borrows the confidence of laboratory terms without carrying their limits. A consent form is not a slogan, and a headline is not a label. When the words are loose, expectations become loose too, and expectations are part of what a trial must manage.

Four words doing too much work

Start with cure. In ordinary British English, a cure suggests the disease has gone and will not return. In gene-editing trials, the more accurate description is often a durable clinical benefit: fewer crises, reduced need for transfusions, or an improved quality of life over a defined follow-up period. That is valuable, but it is not the same claim. A patient who reads cure may stop attending monitoring appointments or assume that conventional care is no longer needed. A journalist who writes cure may turn a phase 1 safety study into a breakthrough.

Treatment is broader, but it can obscure whether the intervention is one-off or continuing. A gene-editing medicinal product may be given once, yet the patient may still need antibiotics, vaccinations, fertility counselling or long-term follow-up. Calling it a treatment is not wrong; failing to say what kind of treatment it is becomes misleading.

Edit describes a mechanism, not an outcome. A successful edit at the intended genomic site does not automatically mean a clinical benefit. It may mean the edit occurred, that some cells carry it, or that a laboratory assay detected the intended change. Those are three different claims. In UK regulatory language, the distinction between an edit and a clinical endpoint is not pedantry; it is the basis of how a trial is assessed.

Functional cure is the most slippery term of all. It can mean that a person no longer shows signs of disease while still carrying the underlying genetic change. It can mean that symptoms are controlled well enough to stop certain treatments. It can mean different things in different disease areas. Without a definition attached, the phrase invites patients to hear the strongest possible version of the claim.

Where the words meet the paperwork

Consent forms are where this matters most. A participant should be able to understand whether a trial is testing safety, whether the editing is somatic and therefore not inherited, whether the intervention is ex vivo or in vivo, and whether standard care will continue. If the form says gene therapy but the protocol describes a gene-editing medicinal product, the participant may not know whether the two are the same. If the patient information sheet says cure while the protocol says improvement in severe vaso-occlusive crises, the mismatch is not a drafting detail. It is an ethical problem.

UK research ethics committees and the Medicines and Healthcare products Regulatory Agency already scrutinise participant information. But scrutiny is not the same as consistency. Different sponsors use different phrases for similar concepts. A shared glossary would not replace regulatory judgement; it would give committees, sponsors and patient representatives a common starting point.

A plain-English glossary worth testing

The beginnings are not difficult. A UK-facing glossary could define somatic gene editing as editing cells in a patient that are not passed to children; germline editing as editing that could be inherited, which is not currently permitted in UK clinical practice; ex vivo as editing cells outside the body before returning them; and in vivo as editing inside the body. It could distinguish base editing and prime editing from conventional CRISPR cutting without implying that one is automatically safer or more effective.

It could also define durable response as a benefit maintained for a stated period, off-target edit as an unintended change at another site in the genome, and mosaic as a situation in which not all cells carry the same edit. These are not fringe terms. They appear in patient conversations, grant applications and news reports, often without explanation.

The harder task is agreeing what cure and functional cure should mean in public communication. One option is to avoid cure unless a clinical claim has been authorised or a trial has demonstrated a defined, lasting outcome. Another is to require the phrase to be followed by a plain-English definition and a statement of what remains uncertain. Neither approach would silence legitimate scientific ambition. Both would make the ambition legible.

The media’s share of the responsibility

British science journalism is not a monolith, and neither is the CRISPR Brief readership. Some outlets report trials with care; others compress a 2,000-word protocol into a headline. The pressure is real. But a headline that says cure when the underlying claim is durable benefit in a small cohort is not a harmless shorthand. It shapes referrals, fundraising and political expectations. It can also make later, more accurate reporting look like a climbdown.

A practical solution is for newsrooms and press offices to use the same small set of outcome words. If a press release says investigational gene-editing therapy, the headline should not say cure. If the trial is assessing safety, the story should say so in the first three paragraphs. These are not restrictions on editorial freedom; they are minimum standards for a field where the difference between an edit and a cure is the difference between a laboratory result and a life changed.

Before the next trial, the next sentence

Britain does not need to wait for another trial to improve this. It needs a lexicon that researchers, regulators, journalists and patient organisations can recognise. The work could sit with an existing body, such as a research funder or a professional society, and should include patients who have already taken part in gene-editing studies. It should be short enough to use, specific enough to be meaningful, and reviewed as the science develops.

Precision in editing is rightly celebrated. Precision in wording deserves the same attention. A shared vocabulary will not answer the hard questions about access, cost or long-term follow-up. It will, however, make those questions clearer. In a field moving as quickly as this one, that is not a cosmetic improvement. It is part of responsible translation.